Join us Thursday 4/24 at 2pm Central Time, as we focus on the valuation range for Ford (F). Register here. HIDE

Geron (GERN)

Add to Watchlists
Create an Alert
2.00 -0.19  -8.68% NASDAQ Apr 23, 8:00PM BATS Real time Currency in USD
View Full Chart
GERN Price Chart
View All Events

GERN Events

Date Type Description
Mar 12 Misc Q4 2013 Geron Corporation Earnings Conference Call
Mar 12 Earnings Q4 2013 Geron Corporation Earnings Results. Estimate: -0.06.
Nov 07 Misc Q3 2013 Geron Earnings Conference Call
Nov 07 Earnings Q3 2013 Geron Earnings Results. Estimate: -0.06.
Aug 08 Misc Q2 2013 Geron Earnings Conference Call
Aug 08 Earnings Second Quarter 2013 Financial Results. Estimate: -0.07.
May 22 Misc AGM Event for Geron Corp.
Apr 26 Misc Q1 2013 Geron Earnings Conference Call
Apr 25 Earnings Geron Announces Conference Call to Discuss First Quarter 2013 Financial Results. Estimate: -0.08.
View All Performance Charts

GERN Total Returns Comparison

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Geron is up 80.18% over the last year vs S&P 500 Total Return up 21.33%, Actelion up 71.93%, and BioTime down 31.66%.

Get Quote for

Portfolio Strategies Featuring GERN

Did Geron make it into our Portfolio Strategies?
Start your YCharts membership now to find out.

GERN Profile

  • Sector: Healthcare
  • Industry: Biotechnology
  • Headquarters Country: United States
  • Headquarters State/Province: California
  • Incorporation Country: United States
  • Incorporation State/Province: Delaware
  • Est. Current Fiscal Quarter End: June 30, 2014
  • Est. Current Fiscal Year End: December 31, 2014
  • Last Fiscal Quarter End: N/A
  • Last Fiscal Year End: N/A
  • NAICS: Pharmaceutical Preparation Manufacturing
  • NAICS Code: 325412
  • NAICS Industry: Pharmaceutical and Medicine Manufacturing
  • NAICS Industry Code: 3254
  • NAICS Sector: Manufacturing
  • NAICS Sector Code: 32

Geron Corporation is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic products for oncology such as telomerase inhibitor, imetelstat and in hematologic myeloid malignancies, among others.

Recent Quotes

Symbol Price Chg Chg % Market Cap
GERN 2.00 -0.19 -8.68% 309.68M
Create Watchlist from Quotes

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

Get Started Now

Upgrade to {{}}. Start Your YCharts Membership. Start your {{}} Membership


{{ ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{}} Member? Sign in here.